Search the Newsreel

Babcock & Wilcox surges as revenue, earnings crush estimates (BW:NYSE)

Babcock & Wilcox Enterprises earnings beat by $0.04, revenue topped estimates

Babcock & Wilcox: Q2 Earnings Snapshot

Babcock & Wilcox (NYSE: BW) swings to Q2 profit, lifts 2026 EBITDA target

Babcock & Wilcox (NYSE: BW) reported a significant financial turnaround in Q2 2026, swinging to a net profit of $14.3 million from a loss of $58.5 million in the prior year, with revenue surging 130% to $319.7 million. The company raised its full-year 2026 …

Babcock & Wilcox (NYSE: BW) swings to Q2 profit on surging project revenue

Portman Ridge Finance Corp (NASDAQ:BCIC) Given Consensus Recommendation of "Reduce" by Brokerages

Portman Ridge Finance Corp (NASDAQ:BCIC) has received a "Reduce" consensus recommendation from five analysts, with one sell and four hold ratings, and an average 12-month price target of $9.25. Recent analyst price target cuts include $7.50 from Keefe, Bruyette & Woods and $11.00 from …

Portman Ridge Finance (NASDAQ:BCIC) Price Target Cut to $11.00 by Analysts at Oppenheimer

Oppenheimer has cut its price target for Portman Ridge Finance (NASDAQ:BCIC) to $11.00 from $12.00, while maintaining a "market perform" rating, suggesting a 46.18% potential upside. Analyst sentiment for the stock is largely cautious, with four analysts rating it "Hold" and one "Sell," leading …

AbCellera stock soars on ‘off the chart’ trial results from hot flash treatment for menopausal women

AbCellera Biologics Inc. saw its stock soar after announcing "off the chart" human trial results for its hot flash treatment, ABCL635, which proved more effective and had fewer side effects than existing therapies. The drug, aimed at menopausal women and those undergoing hormone-suppressing cancer …

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera has announced positive top-line results from its Phase 2 clinical trial for ABCL635, an investigational antibody for treating moderate-to-severe vasomotor symptoms (hot flashes) in menopausal women. The study demonstrated statistically significant reductions in both the frequency and severity of symptoms, as well as …

BCB Bancorp (BCBP) swings to $14.8M Q2 loss as credit costs and goodwill hit

HSBC (HSBC) buys back 340,000 shares in Hong Kong as part of 2026 programme

HSBC Holdings plc announced the repurchase of 340,000 ordinary shares on August 10, 2026, through the Hong Kong Stock Exchange, as part of its share buy-back program initiated on August 5, 2026. The shares were bought at prices ranging from HK$161.6000 to HK$162.8000. Since …

AbCellera Biologics Sees Unusually High Options Volume (NASDAQ:ABCL)

AbCellera Biologics (NASDAQ:ABCL) experienced unusually high options trading volume, with investors purchasing 16,666 call options, a 151% increase over the average. The company's shares surged by $2.37 to $9.30 on heavy trading volume, despite missing analyst expectations for both earnings and revenue in its …

Analysts Offer Insights on NA Companies: Once Upon a Farm, PBC (OFRM) and Deep Fission (FISN)

Two analysts have offered bullish insights on NA sector companies Once Upon a Farm, PBC (OFRM) and Deep Fission (FISN). Goldman Sachs reiterated a Buy rating on Once Upon a Farm with a $23.40 average price target, while Seaport Global initiated coverage on Deep …

Keefe, Bruyette & Woods Issues Pessimistic Forecast for Portman Ridge Finance (NASDAQ:BCIC) Stock Price

HSBC downgrades Akamai to hold, cuts target price to $123

Investing.com -- HSBC downgraded Akamai Technologies to Hold from Buy and cut its target price to $123 from $171, citing weaker cloud infrastructure margins and slower long-term growth. The new target implies 3.8% upside from the $118.55 share price as of Aug. 6. Akamai …

Abcellera Biologics stock hits 52-week high at 8.79 USD

Abcellera Biologics Inc. (ABCL) reached a 52-week high of $8.79, reflecting a 63% total return over the past year and 119% over six months. Despite this, an InvestingPro analysis suggests the stock may be overvalued. The company also announced positive Phase 2 clinical trial …

Why is Abcellera Biologics stock surging today?

Abcellera Biologics (ABCL) stock surged over 30% in pre-open trading after its antibody, ABCL 635, met the primary efficacy endpoint in a Phase 2 clinical trial for menopausal hot flashes, showing an 83% reduction in frequency. This clinical success, combined with strong analyst conviction …

BCE Inc. (BCE) refreshes ethics and conduct Code covering trading, AI and privacy

BCE Inc. has updated its Code of Business Conduct to reinforce ethical and compliance expectations for all directors, executives, and employees, including Canadian subsidiaries. The refreshed Code addresses critical areas such as insider trading, responsible AI use, data privacy, and conflict of interest management. …

AbCellera's ABCL635 Delivers Strong Phase 2 Data; Stock Jumps 33%

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational NK3R antagonist antibody for moderate-to-severe vasomotor symptoms due to menopause. The study met its primary efficacy endpoints achieving statistically …

AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

AbCellera Biologics announced positive top-line results from its Phase II trial of ABCL-635, a non-hormonal treatment for menopausal hot flashes. The study showed an 83% reduction in moderate-to-severe hot flashes, along with improvements in symptom severity and sleep disturbance, and a favorable tolerability profile. …

ABCL Stock Rips As Vertex Deal And Data Catalyst Fire Up Traders

AbCellera Biologics Inc. (ABCL) stock surged over 24% due to strong optimism surrounding its antibody discovery platform, a new collaboration with Vertex Pharmaceuticals, and upcoming Phase 2 data for ABCL635. The Vertex deal provides $28 million upfront, with potential milestones and royalties, validating ABCL's …

Weekly Recap: Q2 adjusted EPS and Bell CTS revenue rise from Ziply Fiber

BCE Inc. (NYSE:BCE) reported Q2 adjusted EPS of C$0.65 and revenue of C$6.18 billion, with net income at C$558 million. Bell CTS's operating revenue increased by 0.4% to C$5.36 billion, largely due to the acquisition of Ziply Fiber, which helped offset weaker Canadian results. …

AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Slashed This Year's Revenue Estimates By 22%

Analysts have significantly revised down AbCellera Biologics Inc.'s (NASDAQ:ABCL) revenue estimates for 2026 by 22%, now forecasting US$25 million, which represents a 62% decline year-over-year. Despite this pessimistic outlook, the company's share price has recently risen by 19%. The updated forecasts suggest AbCellera Biologics …

Coca Cola HBC stock falls on analyst downgrade

Royal Bank of Canada Increases Stake in Planet Labs PBC $PL

HSBC Holdings, plc. Revenue Breakdown – BOATS:HSBC

This article provides a revenue breakdown for HSBC Holdings, plc., highlighting its top-performing segment and the geographical region contributing the most to its revenue. Last year, the company generated $71.00 billion USD, with Corporate and Institutional Banking being the largest segment. The greatest contribution …

BCB Bancorp Inc (BCBP) Earnings Forecast: Future EPS & Revenue Growth Estimates

FY2027 EPS Estimates for HSBC Increased by Erste Group Bank

Erste Group Bank has raised its FY2027 earnings per share estimate for HSBC to $9.35, up from $9.30, while maintaining a "Hold" rating on the stock. This revised estimate is above the current consensus of $8.62. Despite recent analyst downgrades from BNP Paribas Exane …

Weekly Recap: HSBC (HSBA) H1 PBT surge and $5.0B tender-funded bonds

HSBC (HSBA) reported strong H1 2026 results with a 23% YoY PBT surge to $19.5B and revenue of $37.7B, alongside robust ROTE and CET1. The bank announced a $1B buyback, ongoing cost cuts, and priced senior bonds to fund a tender offer of up …

Weekly Recap: H1 profit jump and 75% Coca‑Cola Beverages Africa purchase

AbCellera To Present Phase 2 Results Of ABCL635 For Menopause Symptoms Today

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced that it will release top-line results from its Phase 2 clinical trial from its Phase 2 clinical trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes due to menopause, before …

Is RBC Bearings (RBC) Pricey On Strong Earnings And Higher Guidance?

Is Planet Labs (PL) Turning Government AI Deals Into a Durable Edge in Geospatial Analytics?

Zevia PBC Q2 Earnings Call Highlights

Key Points Interested in Zevia PBC? Here are five stocks we like better. Q2 sales increased 1.1% to $45 million, while adjusted EBITDA improved to approximately $0.5 million from $0.2 million a year earlier. Gross margin edged up to 48.9%, although higher aluminum costs …

BCI Minerals Ltd (BC3) Q2 2024 Earnings Report - Results, Call & Slides

Amundi Sells 9,461 Shares of RBC Bearings Incorporated $RBC